Botulinum toxin type A for the treatment of lower urinary tract disorders. - Wikidata - awgldk - TriplyDB

Botulinum toxin type A for the treatment of lower urinary tract disorders.

Botulinum toxin type A for the treatment of lower urinary tract disorders.

http://www.wikidata.org/entity/Q37973408

about

Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use.Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis.Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis--Different Mechanisms of Action of Botox on Bladder Dysfunction?Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis.Botulinum neurotoxin-A treatment of lower urinary tract symptoms in multiple sclerosis.The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review.Emerging drugs for autonomic dysfunction in Parkinson's disease.Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice.The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis.Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity.Characteristics Associated with Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence Botulinum toxin type A injection for neurogenic detrusor overactivity: clinical outcome in Japanese patients.Complications after bladder augmentation in children.

P2860

Q26851170-A6C5C1C6-88DF-4F9A-AAA2-52162962CD22 Q33665035-FEECE4A1-9FC9-4E34-972C-C8B25BB1A932 Q33671401-47082AD8-227F-42DF-83D1-7C51516B16F1 Q35798421-71EEF9A8-A46C-4F08-A30D-017A0F2FA7C5 Q36735590-D6E697D6-4456-4AE4-AA30-C7818D4AB8C3 Q36804908-FB293A32-3A22-4567-B736-5CB15277483A Q37496473-59032186-8963-41CE-B45C-DB9ED7824D9D Q38034119-6939A5F6-E535-4F11-AE70-2EE63ADCFD20 Q38078434-F435AD7A-7A82-491C-B32A-D5896C9828D6 Q38184544-F4177947-4389-4055-8F3E-4D9714D7DD06 Q38200003-91F804B5-66D6-43BD-B90C-912BD80BE2D7 Q38210146-14FD811D-CE7C-4479-9D45-EF7BB710C7A3 Q38544122-CBB48625-C3FF-47C6-9E6E-7789F9606654 Q38660550-44DA9D5B-A366-4E65-A3D1-508120C904A9 Q38787744-50464282-22E7-408A-A362-95A2458CFD7F Q44393431-F0F02DA8-E5D5-4E2A-A264-9DD1994FB46E Q53107823-479ECF6B-2CFE-4C5B-9920-98DF8D81249E

P2860

Botulinum toxin type A for the treatment of lower urinary tract disorders.

http://www.wikidata.org/entity/Q37973408

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@en

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@nl

type

label

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@en

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@nl

prefLabel

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@en

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@nl

P1433

Q37973408-F6DCC2C1-B5D5-46BF-A944-91E0C20A6655

P1476

Q37973408-A03D1095-088F-4BC5-B274-5E72144935F6

P2093

Q37973408-11A1F4F9-989A-45DE-942B-A20C275B2DBB

Q37973408-2C478F1D-5CFA-4323-99C4-F594771F6FD0

Q37973408-334BD5AA-5CB7-46CE-B83C-57E063E982C4

Q37973408-69534ED8-216F-4480-B3BD-7DE99C8A5046

Q37973408-82B3F648-C585-4844-8EDF-ED68CBAF1F6B

Q37973408-CA0B7520-B9CE-48FF-AA21-1C03FA116246

Q37973408-E712187B-0DCF-4949-86EE-F10F63CE5405

P2860

Q37973408-0096584D-2330-4589-90C4-68684C6E837F

Q37973408-012DF1D8-527B-4063-8C6C-3FCED606792C

Q37973408-0B65BBCC-CD25-4295-93CA-165BB6F9D91F

Q37973408-0D77BB7B-B68D-41BB-8DED-1A489222CB09

Q37973408-0E8A0160-70C9-4160-8363-22A3D5706BB8

Q37973408-115E467A-B315-4E98-887F-8302D16355BB

Q37973408-205DDEFC-3C86-4B80-AA60-31DD0703D642

Q37973408-2487DA95-4FE7-427C-9F17-540963FBB918

Q37973408-2CEBC40F-FAC8-4E22-BC77-9F95966AF242

Q37973408-3433FF00-F23C-4DED-9A59-CE71C79DB53C

P304

Q37973408-8CAAD0BC-F86F-470A-8018-BE73C604D3FE

P31

Q37973408-A27E0F52-BDE6-464F-A549-7F850D78614C

P356

Q37973408-89CCDB88-9B1F-4B3A-BF72-B32ACED02138

P433

Q37973408-4F9D247F-77E2-47E6-92D5-6D504ED840E9

P478

Q37973408-537D5932-73FC-46F3-B067-88D1BF27873E

P577

Q37973408-58C0412B-BCD1-42E6-BE60-49FEF5384A88

P5875

Q37973408-46A33B84-463C-4708-A9E4-5DEE76AF11C0

P698

Q37973408-F5623B3B-BD43-4C75-8C2D-F5E1681FED87

P356

J.1442-2042.2011.02946.X

P1433

International Journal of Urology

P1476

Botulinum toxin type A for the treatment of lower urinary tract disorders.

@en

P2093

Atsushi Nagai

http://www.w3.org/2001/XMLSchema#string

Hiromi Kumon

http://www.w3.org/2001/XMLSchema#string

Keiji Oguma

http://www.w3.org/2001/XMLSchema#string

Michael B Chancellor

http://www.w3.org/2001/XMLSchema#string

Teruhiko Yokoyama

http://www.w3.org/2001/XMLSchema#string

Tomonori Suzuki

http://www.w3.org/2001/XMLSchema#string

Yumiko Yamamoto

http://www.w3.org/2001/XMLSchema#string

P2860

A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.

Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature.

Emerging role of botulinum toxin in the management of voiding dysfunction.

Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial

Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.

Refractory idiopathic urge urinary incontinence and botulinum A injection.

Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.

P304

202-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1442-2042.2011.02946.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221725603

http://www.w3.org/2001/XMLSchema#string

P698

22220916

http://www.w3.org/2001/XMLSchema#string